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Introduction: MicroRNA-101 (miR-101) is frequently downregu-
lated in cancer and exhibits antitumorigenic properties, suggesting
that miR-101 is a putative tumor suppressor. miR-101 is encoded at
two loci in the human genome: 1p31.3 (miR-101-1) and 9p24.1
(miR-101-2). We sought to investigate miR-101 locus-specific de-
letions and genomic loss in the major subtypes of lung cancer.
Methods: Analyses of high-resolution array comparative genomic
hybridization and single-nucleotide polymorphism array data were
performed to determine the DNA copy number status and deletion
boundaries of miR-101-1 and miR-101-2 in seven independent
cohorts that comprised 1236 lung cancer specimens and 20 lung
carcinoma in situ samples. miR-101 expression was also investi-
gated in lung cancer cell lines and tumors.
Results:miR-101 loss at either genomic locus was identified in 29%
of lung cancers analyzed and was associated with reduced miR-101
expression. Loss was more frequent at the 9p locus and occurred
more often in NSCLC as opposed to small cell lung cancer. Lung
carcinoma in situ also harbored miR-101 deletions, suggesting that
genomic loss may be an early event in lung cancer development.
Finally, miR-101 deletions on 9p were exclusive of CDKN2A
deletions in several cases, providing evidence that loss of miR-101
is not merely a passenger of CDKN2A deletion.
Conclusions: miR-101 genomic loss occurs frequently in NSCLC
and may be an early event in lung tumorigenesis. DNA deletions
likely represent a prominent molecular mechanism of miR-101
downregulation in NSCLC but not in small cell lung cancer.
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(J Thorac Oncol. 2011;6: 1594–1598)
MicroRNAs (miRNAs) are frequently deregulated in can-cer.1 Expression profiling has revealed several miRNA
signatures associated with classification, prognostics, and
therapeutic response.2 miRNA-101 (miR-101) is frequently
underexpressed in multiple malignancies including prostate,
liver, lung, bladder, and gastric cancers.3–10 Overexpression
of miR-101 has tumor-suppressive effects, such as inhibition
of cell migration, invasion, proliferation, and promotion of
apoptosis, and miR-101 is known to negatively regulate
oncogenes such as EZH2.3–6,10 Several molecular mecha-
nisms may account for aberrant miR-101 expression; for
example, genomic loss is a mechanism of downregulation in
prostate and other cancers.1,5 Intriguingly, miR-101 has two
encoding loci at 1p31.3 (miR-101-1) and 9p24.1 (miR-101-
2). Herein, we report locus-specific deletions and lung cancer
subtype-specific patterns of miR-101 genetic disruption.
MATERIALS AND METHODS
The DNA copy number status of miR-101-1 and miR-
101-2 were determined for 261 lung tumors (169 adenocar-
cinomas [ACs], 92 squamous cell carcinomas [SCCs]) and 20
lung carcinoma in situ (CIS) by tiling path array comparative
genomic hybridization (aCGH) as previously described with
BC Cancer Agency Research Ethics Board approval.11 aCGH
and single-nucleotide polymorphism (SNP) array data for an
additional 975 lung cancer samples of diverse subtypes were
compiled from five independent lung cancer datasets (Table
1). SNP array data were analyzed using Partek Genomics
Suite software (Partek Incorporated, St. Louis, MO). Copy
number profiles for dbGaP (Database of Genotypes and
Phenotypes) tumors were generated using matched nonma-
lignant profiles from the same individual as a reference, and
Max-Planck Institute tumor profiles were generated using a
pool of 59 nonmalignant tissues as a copy number baseline.
Cell line profiles were generated using data for 72 cytoge-
netically normal HapMap individuals as a reference.12 Copy
number profiles for MSKCC and NCI aCGH data were
generated using the segmentation algorithm, FAC¸ADE.13
Data for each sample set were systematically screened to
determine the frequency of miR-101 genomic loss at both
loci using the following genomic coordinates (hg18) from
the UCSC genome browser: miR-101-1 chr1:65296704-
65296779 bp and miR-101-2 chr9:4840296-4840375 bp
(http://genome.ucsc.edu/cgi-bin/hgGateway). Real-time quant-
itative polymerase chain reaction was performed to assess
miR-101 expression levels in 25 NSCLC tumor normal pairs
using TaqMan primers for miR-101 and U6 snRNA as an
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endogenous control (assay IDs: 002253 and 001973, respec-
tively). Statistical analyses are described below.
RESULTS
To investigate the presence and locus-specific patterns
of miR-101 genetic disruption, we first screened 261 tumors
using high-resolution aCGH. Loss of either miR-101 locus
(1p and/or 9p) was prevalent, occurring in 39% of these
tumors. Although, loss at 9p (34%) and 1p (18%) were not
mutually exclusive, 69% of the 103 tumors with miR-101
loss had loss at only one locus (Table 1).
To verify that our findings were not limited to the
British Columbia (BC) tumors alone, we repeated our anal-
ysis with data from five external cohorts. Deletion was
detected in 24% of the 847 lung tumors and 48% of the 128
lung cancer cell lines (Table 1, Figure 1A). Consistent with
the BC patient cohort, the majority of cases (84%) showed
deletion at only one miR-101 locus. Moreover, genomic loss
of miR-101-2 (9p) was more prevalent than loss of miR-
101-1 (1p) in each dataset.
To determine whether miR-101 gene deletion is equally
common among the major subtypes of lung cancer, we first
examined lung cancer cell lines. Genomic loss was more
prevalent in NSCLC than in SCLC (Fisher’s exact test, p 
8.3  106) (Figure 1B). The frequency of loss was high in
both AC and SCC subtypes of NSCLC (76% and 40%,
respectively) but less frequent in SCLC (23%). miR-101 loss
was also more prevalent in NSCLC tumors (28%) than SCLC
tumors (12%) despite the limited number of SCLC tumors
available for analysis (Fisher’s exact test, p  0.048). As in
cell lines, the frequency of miR-101 loss was not statistically
different between AC and SCC tumors.
MiRNA expression data were available for 117 of the
128 lung cancer cell lines. miR-101 expression was signifi-
cantly lower in cell lines with genomic loss versus those
without (U test, p  0.0001). In 25 NSCLC tumors, miR-101
TABLE 1. Summary of miR-101 Loss in Seven Independent Lung Cancer and Lung CIS Datasets
Dataset Source Data Type No. of Samples
Frequency
of Loss at
Either
Locusa
Frequency
of Loss at
1p Locus
Frequency
of Loss at
9p Locus
Proportion
of Cases
with Single
Locus Lossb
BCCRC Lung
CIS
BCCRC SMRT Array
CGH
20 CIS 0.8500 (17) 0.3000 (6) 0.7000 (14) 0.8235 (14)
BCCRC
Tumors
BCCRC SMRT Array
CGH
261 NSCLC (169AC,
92 SCC)
0.3946 (103) 0.1762 (46) 0.3410 (89) 0.6893 (71)
Sanger Lung
Cancer Cell
Lines
SNP array: Wellcome Trust
Sanger Institute CGP Data
Archivec (sanger.ac.uk/
genetics/CGP/Archive/)
SNP 6 Array and
Affymetrix
U133A
128 (69 NSCLC, 53
SCLC, 16 other)
0.4766 (61) 0.1094 (14) 0.4141 (53) 0.9016 (55)
Expression (117/128 lines
with SNP data): Broad
Institute Sanger Cell Line
Project (broadinstitute.
org/cgi-bin/cancer/
datasets.cgi)
DbGaP
Tumors
dbGaP Genotypes and
Phenotypes
databased (Study
Accession:
phs000144.v1.p1)
SNP 250K Array 383 NSCLC 0.1749 (67) 0.0522 (20) 0.1488 (57) 0.8507 (57)
MSKCC
Tumors
Memorial Sloan-Kettering
Cancer Centre (http://
cbio.mskcc.org/Public/
lung_array_data/)
Agilent 44K Array
CGH
199 AC 0.1055 (21) 0.0000 (0) 0.1055 (21) 1.0000 (21)
Max-Planck
Tumors
Gene Expression Omnibus
Accession: GSE25016
SNP 6 Array 232 NSCLC (155
SCC, 77 AC)
0.4655 (108) 0.1810 (42) 0.3879 (90) 0.7778 (84)
NCI Tumors Gene Expression Omnibus
Accession: GSE21468
Agilent 105A and
4  180k Array
CGH
33 SCLC 0.1212 (4) 0.0606 (2) 0.0909 (3) 0.75 (3)
Totals 1256 0.3033 (381) 0.1035 (130) 0.2604 (327) 0.8005 (305)
Numbers in brackets in columns 5 to 8 indicate the number of cases with miR-101 loss.
a Proportion of total samples with miR-101 deletions at 1p or 9p or both.
b Proportion of samples harboring miR-101 loss with loss at only one locus (i.e., 1p or 9p but not both).
c Declaration required by the data source: SNP 6.0 cell line data were downloaded from the Wellcome Trust Sanger Institute CGP Data Archive (sanger.ac.uk/genetics/CGP/
Archive/). Authors declare that those who carried out the original analysis and collection of the data bear no responsibility for the further analysis or interpretation of it by the authors.
d We would like to acknowledge the National Human Genome Research Institute (NHGRI), the Tumor Sequencing Project (TSP) consortium, laboratories at the Dana Farber
Cancer Institute, Memorial Sloan-Kettering Cancer Center, and Washington University’s Siteman Cancer Center, and funding from the National Institutes of Health (U54HG003067,
U54HG003079, and U54HG003273) for access to the dbGaP dataset phs000144.v1.p1.
BCCRC, British Columbia Cancer Research Centre; dbGaP, Database of Genotypes and Phenotypes; MSKCC, Memorial Sloan-Kettering Cancer Center; NCI, National Cancer
Institute.
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expression was also correlated with DNA copy number status
as expression was significantly lower in tumors with genomic
loss versus those without (U test, p  0.0289) (Figure 2).
Concordant with the subtype-specific DNA copy number
findings, miR-101 expression was significantly higher in
SCLC compared with NSCLC lines (U test, p  0.0001)
(Figure 1C). There was no significant difference in expres-
sion levels between AC and SCC subtypes in cell lines or
tumors.
We also looked for clinicopathological associations
with miR-101 genomic loss in one dataset with available
clinical information. In the MSKCC tumors, 21 of 199
harbored miR-101 genomic loss. The limited power of this
dataset likely contributed to our inability to identify any
significant associations between miR-101 genomic loss and
patient outcome, EGFR and KRAS mutation status, tumor
recurrence, or smoking status.
Finally, we asked whether miR-101 genomic loss may
be an early event in lung tumorigenesis. We examined 20 CIS
cases and found that the majority (85%) harbored deletions at
the 1p or 9p loci. Of the 17 cases with loss, 82% showed
deletion at only one locus (Table 1, Figure 3).
DISCUSSION
miR-101 is a putative tumor suppressor often down-
regulated in cancers.3–6,10 In prostate cancer, genomic loss is
a recurrent event that results in miR-101 downregulation and
consequential overexpression of its target gene, EZH2.5 miR-
101 DNA loss has been detected in acute lymphoblastic
leukemias; gastric, breast, and prostate cancers; glioblastoma;
and lung adenocarcinoma.5 Interestingly, a recent report de-
scribed genomic loss as a mechanism of miR-486 downregu-
lation in gastric cancer, suggesting that DNA deletion may be
a common mechanism of miRNA inactivation in a broad
range of cancers.14 In this study, we investigated several large
lung cancer cohorts to determine whether (1) miR-101 DNA
deletion is a prominent event in lung cancer, (2) there are
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FIGURE 1. miR-101 genomic loss in lung cancer cell lines. A, miR-101 genomic losses at the 1p and 9p loci occur predomi-
nantly at one locus or the other. Of the 61 lung cancer cell lines with miR-101 genomic loss (indicated by gray boxes), 55
(90%) had deletions at only one miR-101 locus. B, DNA deletions of miR-101 are more frequent in non-small cell lung cancer
(NSCLC) than in small cell lung cancer (SCLC) (Fisher’s exact test, p  8.3  106) and are more frequent in the adenocarci-
noma subtype than in the squamous cell carcinoma subtype. C, Expression levels of miR-101 are higher in SCLC cell lines than
in NSCLC cell lines (U test, p  0.0001).
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FIGURE 2. Correlation of miR-101 genomic loss and ex-
pression in non-small cell lung cancer (NSCLC) tumors. miR-
101 expression was assessed by quantitative polymerase
chain reaction in 25 NSCLC tumor normal pairs. Expression
of miR-101 is lowest in tumors with genomic loss and in-
creases with increase in gene dosage.
Thu et al. Journal of Thoracic Oncology • Volume 6, Number 9, September 2011
Copyright © 2011 by the International Association for the Study of Lung Cancer1596
lung cancer subtype-specific patterns of miR-101 genetic
disruption, (3) genomic loss is an early event, and (4) one of
the 2 miR-101 genes is preferentially deleted.
A recent study demonstrated frequent downregulation
of miR-101 in NSCLC and demonstrated that re-expression
had tumor suppressive effects, consistent with findings in
other cancer types; however, the genetic mechanism driving
miR-101 underexpression in these NSCLC tumors was not
investigated.10 We interrogated the frequency of miR-101
genomic loss in samples representing various lung cancer
types. We screened a total of five independent lung cancer
cohorts, analyzing 1236 lung cancer samples in addition to 20
lung CIS. Collectively, miR-101 genomic loss was observed
in 30% of specimens analyzed. The high frequency of miR-
101 deletion rivals the frequencies of genomic alteration to
other well-known lung cancer genes such as EGFR, TITF1,
KRAS, and LKB1 which are altered in approximately 10 to
40% of lung cancers.15 Therefore, we conclude that miR-101
genomic loss is a prominent, recurrent event in lung cancer.
Importantly, we found that miR-101 genomic loss was asso-
ciated with low expression in both cell lines and tumors,
suggesting that loss is a major mechanism of miR-101 down-
regulation in lung cancer.
It is becoming increasingly apparent that the histolog-
ical subtypes of lung cancer exhibit distinct clinical behaviors
that are likely driven by subtype specific molecular altera-
tions. In light of this, we assessed the prevalence of miR-101
deletions in the three major types of lung cancer (AC, SCC,
and SCLC). There was no significant difference in the prev-
alence of miR-101 deletions in AC and SCCs. However, we
found that miR-101 genomic loss occurs preferentially in
NSCLC as opposed to SCLC and that this difference is
maintained at the expression level, as miR-101 expression
was elevated in SCLC relative to NSCLC. This finding
corroborates a previous observation in a smaller sample set in
which miR-101 expression was higher in SCLC versus
NSCLC cell lines.16 Considering EZH2 is a known down-
stream target of miR-101, the difference in miR-101 copy
number loss in NSCLCs and SCLCs, which corresponds to
differential miR-101 expression, may suggest different mech-
anisms of EZH2 activation in these lung cancer types.
SCC is thought to evolve through a stepwise histo-
pathological progression from abnormal lung dysplasia to
CIS and finally to invasive cancer. To determine whether
miR-101 DNA deletions are present in early-stage disease,
we examined preinvasive lung lesions. Although our analysis
was limited to 20 lung CIS samples due to the rarity of these
specimens, we detected frequent miR-101 genomic loss,
indicating that it could be an early event in the malignant
transformation of bronchial epithelial cells. This observation
is consistent with the finding that miR-101 is downregulated
in the earliest stages of carcinogenesis.17
miR-101 is coded for at genomic loci on chromosomes
1p (miR-101-1) and 9p (miR-101-2). Higher frequency of
miR-101 loss at the 9p locus was observed in every dataset,
which suggests that the 9p locus may be preferentially al-
tered. Interestingly, miR-101-1 and miR-101-2 deletions oc-
curred at only a single locus in 80% of all analyzed lung
samples harboring deletions. However, we did not observe
any rare events, such as homozygous deletions spanning
either miR-101 locus in any of the datasets interrogated.
CDKN2A, 17.1 Mbp centromeric of the miR-101-2
locus, is the most well-known tumor suppressor located on
chromosome 9p and is thought to be the primary driver gene
of 9p DNA deletion events in cancer. As such, it could be
argued that the high frequency of miR-101 loss observed is
simply a side effect of large deletions targeting CDKN2A.
However, in every cohort analyzed except for the SCLC
tumors, we detected cases harboring miR-101-2 deletions in
the absence of CDKN2A genomic loss. Thus, it is apparent
that miR-101-2 and CDKN2A are not always codeleted,
providing evidence that miR-101-2 deletions are not simply
passengers of CDKN2A alterations.
In addition to providing biological insight into potential
mechanistic differences in the major lung cancer types, miR-
101 genomic loss and consequential downregulation have
clinical implications. Although we did not observe any sig-
nificant associations between miR-101 genomic loss and
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FIGURE 3. miR-101 genomic loss
in lung carcinoma in situ (CIS). miR-
101 genomic losses were detected in
lung CIS samples and deletions at
the 1p and 9p loci were mutually
exclusive in all but three cases (CIS3,
CIS8, and CIS9). Regions for the
lung CIS harboring miR-101
genomic loss are illustrated by hori-
zontal lines, and genomic positions
are shown relative to their chromo-
somal locations. CDKN2A status is
also indicated.
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clinical features in the MSKCC dataset analyzed, which is
limited in the number of cases with miR-101 deletion, low
miR-101 expression in endometrial serous adenocarcinoma is
significantly associated with poor survival.18 miR-101 is also
associated with therapeutic response in vitro, as enforced
expression sensitizes cancer cells to chemo- and radiothera-
pies.10,19 Because of its tumor suppressive effects in vivo, it
has been suggested that miR-101 could be developed as a
therapeutic agent to target oncogenes such as EZH2. The
findings of this and other studies provide sufficient evidence
to warrant a prospective study of sufficient scale including the
collection of well-annotated clinical information to investi-
gate associations of miR-101 copy number loss and expres-
sion in a clinical setting.
In summary, our analysis revealed miR-101 was pref-
erentially lost in NSCLC compared with SCLC. Genomic
loss was present in a 30% of lung cancers and CIS, making
the frequency of miR-101 genetic disruption comparable to
that of other established lung cancer genes such as EGFR.
Integration of miR-101 copy number status and expression
revealed a significant correlation, demonstrating that genomic
loss causes a decrease in miR-101 expression. We also
discovered miR-101 loss is an early event in NSCLC devel-
opment and that miR-101 disruption predominantly occurs at
the 9p locus only. In conclusion, we propose that genomic
loss is a prominent subtype-specific mechanism of miR-101
disruption in NSCLC which may have an important role in
NSCLC development.
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